DUNAD

Serial Number 90022032
Registration 6542240
700

Registration Progress

Application Filed
Jun 26, 2020
Under Examination
Approved for Publication
Aug 17, 2021
Published for Opposition
Aug 17, 2021
Registered
Nov 2, 2021

Trademark Image

DUNAD

Basic Information

Serial Number
90022032
Registration Number
6542240
Filing Date
June 26, 2020
Registration Date
November 2, 2021
Published for Opposition
August 17, 2021
Drawing Code
4000

Status Summary

Current Status
Active
Status Code
700
Status Date
Nov 2, 2021
Registration
Registered
Classes
005 042

Rights Holder

DUNAD THERAPEUTICS LTD

16
Address
30 BROAD STREET
GREAT CAMBOURNE
CAMBRIDGE CB23 6HJ

Ownership History

Warhead Ltd

Original Applicant
99
London GB

DUNAD THERAPEUTICS LTD

New Owner Before Publication #1
16
CAMBRIDGE

DUNAD THERAPEUTICS LTD

Owner at Publication
16
CAMBRIDGE

DUNAD THERAPEUTICS LTD

Original Registrant
16
CAMBRIDGE

Legal Representation

Attorney
Kimberly Gambrel

USPTO Deadlines

Next Deadline
845 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2021-11-02)
Due Date
November 02, 2027
Grace Period Ends
May 02, 2028
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

31 events
Date Code Type Description
Nov 2, 2021 R.PR A REGISTERED-PRINCIPAL REGISTER
Aug 17, 2021 PUBO A PUBLISHED FOR OPPOSITION
Aug 17, 2021 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 28, 2021 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 15, 2021 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 23, 2021 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 23, 2021 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 23, 2021 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 2, 2021 CNRT R NON-FINAL ACTION WRITTEN
Apr 2, 2021 GNRT O NON-FINAL ACTION E-MAILED
Apr 2, 2021 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 8, 2021 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 8, 2021 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 4, 2021 ALIE A ASSIGNED TO LIE
Feb 25, 2021 ERSI I TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Jan 27, 2021 ASGN I AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Nov 30, 2020 CNSL R SUSPENSION LETTER WRITTEN
Nov 30, 2020 GNSL S LETTER OF SUSPENSION E-MAILED
Nov 30, 2020 GNS3 O NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Nov 24, 2020 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 24, 2020 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 19, 2020 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 5, 2020 CNRT R NON-FINAL ACTION WRITTEN
Oct 5, 2020 GNRT F NON-FINAL ACTION E-MAILED
Oct 5, 2020 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 29, 2020 DOCK D ASSIGNED TO EXAMINER
Jul 23, 2020 AMPX O PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Jul 23, 2020 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 14, 2020 ALIE A ASSIGNED TO LIE
Jul 2, 2020 PARI I TEAS VOLUNTARY AMENDMENT RECEIVED
Jun 30, 2020 NWAP I NEW APPLICATION ENTERED

Detailed Classifications

Class 005
pharmaceutical preparations for pain, cancer, autoimmune disease, inflammatory disease, neurological disease, psychiatric disease, cardiovascular disease, metabolic disease, endocrine disease, musculoskeletal disease, genetic disease, gastrointestinal disease, haematological disease, respiratory disease, infectious disease, ophthalmological disease, renal disease, hepatic disease, urological disease, gynaecological disease, dermatological disease; Medical preparations for pain, cancer, autoimmune disease, inflammatory disease, neurological disease, psychiatric disease, cardiovascular disease, metabolic disease, endocrine disease, musculoskeletal disease, genetic disease, gastrointestinal disease, haematological disease, respiratory disease, infectious disease, ophthalmological disease, renal disease, hepatic disease, urological disease, gynaecological disease, dermatological disease; Veterinary preparations for cats, dogs, pets, livestock
First Use Anywhere: 0
First Use in Commerce: 0
Class 042
scientific research in the pharmaceutical field; pharmaceutical research and development services; providing scientific research information in the field of pharmaceutical research and development
First Use Anywhere: 0
First Use in Commerce: 0

Classification

International Classes
005 042